Antibiotic use and risk of anti-drug antibody (ADA) formation in inflammatory bowel disease: ADA production was increased in patients treated with cephalosporins or penicillins plus beta-lactamase inhibitors, but decreased following macrolides or fluorchinolones in an Israelian patient cohort.
Haifer C et al, Lancet Gastroenterol Hepatol. 2022; 7(2):141–51
Lyophilized oral fecal microbiota transplantation (FMT) for ulcerative colitis: Antibiotics followed by orally administered FMT was associated with induction of remission in a pilot trial. It was also effective to mediate remission in a small explorative cohort.
Danese S et al, Lancet Gastroenterol Hepatol. 2022; 7(2):118–27
Etrolizumab versus Infliximab for the treatment of moderately to severely active ulcerative colitis: The β7 integrin antibody etrolizumab was not superior to infliximab in a head-to-head phase 3 trial, but performed similarly from a clinical point of view.
Hirode G et al, Gastroenterology. 2022;162(3):757–71.e4
Functional cure after nucleos(t)ide analogue withdrawal in chronic hepatitis B: The best candidates for nucleos(t)ide analogue withdrawal are virally suppressed, HBeAg-negative, non-cirrhotic patients with low HBsAg levels, particularly Whites with < 1000 IU/ml and Asians with < 100 IU/ml. However, strict surveillance is recommended to prevent deterioration.
International Autoimmune Hepatitis Group proposes criteria for response to therapy in autoimmune hepatitis: A consensus process initiated by the International Autoimmune Hepatitis Group (IAIHG) proposes the following criteria:
– Complete biochemical response: normalization of serum transaminases and immunoglobulin G (IgG) below the upper limit of normal at 6 months after initiation of treatment.
– Insufficient response by 6 months: failure to meet the above definition.
– Non-response: < 50% decrease of serum transaminases within 4 weeks after initiation of treatment.
– Remission: liver histology with a Hepatitis Activity Index < 4/18.
– Intolerance to treatment: any adverse event possibly related to treatment leading to potential drug discontinuation.
Updated efficacy and safety data of atezolizumab plus bevacizumab versus sorafenib in unresectable hepatocellular carcinoma: Even after an additional 12-months follow-up of the IMbrave150 study, atezolizumab plus bevacizumab maintained clinically meaningful survival benefits over sorafenib. After a median 15.6 (range, 0–28.6) months of follow-up, the median overall survival was 19.2 months (95% confidence interval [CI]: 17.0–23.7) with atezolizumab plus bevacizumab and 13.4 months (95% CI: 11.4–16.9) with sorafenib (hazard ratio = 0.66; 95% CI: 0.52–0.85; descriptive p < 0.001).
Hirano I et al, Clin Gastroenterol Hepatol. 2022;20(3):525–34.e10
Topical steroid suspension to treat eosinophilic esophagitis:Budesonide oral suspension (2 mg twice daily) was superior to placebo in improving histologic, symptomatic and endoscopic outcomes over 12 weeks in a randomized phase 3 trial involving 318 patients.
Impact of Helicobacter pylori infection on the efficacy of cancer immunotherapies: A translational study revealed that H. pylori infection negatively affects the response to cancer immunotherapies and suggests that H. pylori serology may be a powerful tool to personalize cancer immunotherapies.
Park JH et al, Gastroenterology. 2022;162(2):509–20.e7
Impact of a metabolic syndrome on the risk to develop pancreatic cancer: Recovery from metabolic syndrome was associated with a reduced risk to develop pancreatic cancer in a nationwide cohort study from Korea.
[cs_element_section _id=”1″ ][cs_element_layout_row _id=”2″ ][cs_element_layout_column _id=”3″ ][cs_element_text _id=”4″ ][cs_element_headline _id=”5″ ][cs_element_text _id=”6″ ][cs_element_text _id=”7″ ][cs_element_button _id=”8″ ][cs_element_video _id=”9″ ][cs_element_text _id=”10″ ][/cs_element_layout_column][/cs_element_layout_row][cs_element_layout_row _id=”11″ ][cs_element_layout_column _id=”12″ ][cs_element_image _id=”13″ ][cs_element_text _id=”14″ ][/cs_element_layout_column][/cs_element_layout_row][cs_element_layout_row _id=”15″ ][cs_element_layout_column _id=”16″ ][cs_element_text _id=”17″ ][cs_element_text _id=”18″ ][cs_element_headline _id=”19″ ][cs_element_button _id=”20″ ][/cs_element_layout_column][cs_element_layout_column _id=”21″ ][cs_element_text _id=”22″ ][cs_element_text _id=”23″ ][cs_element_headline _id=”24″ ][cs_element_button _id=”25″ ][/cs_element_layout_column][cs_element_layout_column _id=”26″ ][cs_element_text _id=”27″ ][cs_element_text _id=”28″ ][cs_element_headline _id=”29″ ][cs_element_button _id=”30″ ][/cs_element_layout_column][/cs_element_layout_row][cs_element_layout_row _id=”31″ ][cs_element_layout_column _id=”32″ ][cs_element_image _id=”33″ ][cs_element_text _id=”34″ ][/cs_element_layout_column][/cs_element_layout_row][cs_element_layout_row _id=”35″ ][cs_element_layout_column _id=”36″ ][cs_element_text _id=”37″ ][cs_element_text _id=”38″ ][cs_element_headline _id=”39″ ]Functional cure after nucleos(t)ide analogue withdrawal in chronic hepatitis B: The best candidates for nucleos(t)ide analogue withdrawal are virally suppressed, HBeAg-negative, non-cirrhotic patients with low HBsAg levels, particularly Whites with < 1000 IU/ml and Asians with < 100 IU/ml. However, strict surveillance is recommended to prevent deterioration.\n\n[/cs_content_seo][cs_element_button _id="40" ][cs_content_seo]Link to Falk Mediacenter\n\n[/cs_content_seo][/cs_element_layout_column][cs_element_layout_column _id="41" ][cs_element_text _id="42" ][cs_content_seo]Text:\n\n[/cs_content_seo][cs_element_text _id="43" ][cs_content_seo]Pape S et al, J Hepatol. 2022;76(4):841–9\n\n[/cs_content_seo][cs_element_headline _id="44" ][cs_content_seo]International Autoimmune Hepatitis Group proposes criteria for response to therapy in autoimmune hepatitis: A consensus process initiated by the International Autoimmune Hepatitis Group (IAIHG) proposes the following criteria:
– Complete biochemical response: normalization of serum transaminases and immunoglobulin G (IgG) below the upper limit of normal at 6 months after initiation of treatment.
– Insufficient response by 6 months: failure to meet the above definition.
– Non-response: < 50% decrease of serum transaminases within 4 weeks after initiation of treatment.
– Remission: liver histology with a Hepatitis Activity Index < 4/18.
– Intolerance to treatment: any adverse event possibly related to treatment leading to potential drug discontinuation.\n\n[/cs_content_seo][cs_element_button _id="45" ][cs_content_seo]Link to Falk Mediacenter\n\n[/cs_content_seo][/cs_element_layout_column][cs_element_layout_column _id="46" ][cs_element_text _id="47" ][cs_content_seo]Text:\n\n[/cs_content_seo][cs_element_text _id="48" ][cs_content_seo]Cheng AL et al, J Hepatol. 2022;76(4):862–73\n\n[/cs_content_seo][cs_element_headline _id="49" ][cs_content_seo]Updated efficacy and safety data of atezolizumab plus bevacizumab versus sorafenib in unresectable hepatocellular carcinoma: Even after an additional 12-months follow-up of the IMbrave150 study, atezolizumab plus bevacizumab maintained clinically meaningful survival benefits over sorafenib. After a median 15.6 (range, 0–28.6) months of follow-up, the median overall survival was 19.2 months (95% confidence interval [CI]: 17.0–23.7) with atezolizumab plus bevacizumab and 13.4 months (95% CI: 11.4–16.9) with sorafenib (hazard ratio = 0.66; 95% CI: 0.52–0.85; descriptive p < 0.001).\n\n[/cs_content_seo][cs_element_button _id="50" ][cs_content_seo]Link to Falk Mediacenter\n\n[/cs_content_seo][/cs_element_layout_column][/cs_element_layout_row][cs_element_layout_row _id="51" ][cs_element_layout_column _id="52" ][cs_element_image _id="53" ][cs_element_text _id="54" ][cs_content_seo]Esophagus Stomach Duodenum\n\n[/cs_content_seo][/cs_element_layout_column][/cs_element_layout_row][cs_element_layout_row _id="55" ][cs_element_layout_column _id="56" ][cs_element_text _id="57" ][cs_content_seo]Text:\n\n[/cs_content_seo][cs_element_text _id="58" ][cs_content_seo]Hirano I et al, Clin Gastroenterol Hepatol. 2022;20(3):525–34.e10\n\n[/cs_content_seo][cs_element_headline _id="59" ][cs_content_seo]Topical steroid suspension to treat eosinophilic esophagitis:Budesonide oral suspension (2 mg twice daily) was superior to placebo in improving histologic, symptomatic and endoscopic outcomes over 12 weeks in a randomized phase 3 trial involving 318 patients.\n\n[/cs_content_seo][cs_element_button _id="60" ][cs_content_seo]Link to Falk Mediacenter\n\n[/cs_content_seo][/cs_element_layout_column][cs_element_layout_column _id="61" ][cs_element_text _id="62" ][cs_content_seo]Text:\n\n[/cs_content_seo][cs_element_text _id="63" ][cs_content_seo]Oster P et al, Gut. 2022;71(3):457–66\n\n[/cs_content_seo][cs_element_headline _id="64" ][cs_content_seo]Impact of Helicobacter pylori infection on the efficacy of cancer immunotherapies: A translational study revealed that H. pylori infection negatively affects the response to cancer immunotherapies and suggests that H. pylori serology may be a powerful tool to personalize cancer immunotherapies.\n\n[/cs_content_seo][cs_element_button _id="65" ][cs_content_seo]Link to Falk Mediacenter\n\n[/cs_content_seo][/cs_element_layout_column][/cs_element_layout_row][cs_element_layout_row _id="66" ][cs_element_layout_column _id="67" ][cs_element_image _id="68" ][cs_element_text _id="69" ][cs_content_seo]Pancreas\n\n[/cs_content_seo][/cs_element_layout_column][/cs_element_layout_row][cs_element_layout_row _id="70" ][cs_element_layout_column _id="71" ][cs_element_text _id="72" ][cs_content_seo]Text:\n\n[/cs_content_seo][cs_element_text _id="73" ][cs_content_seo]Park JH et al, Gastroenterology. 2022;162(2):509–20.e7\n\n[/cs_content_seo][/cs_element_layout_column][/cs_element_layout_row][cs_element_layout_row _id="74" ][cs_element_layout_column _id="75" ][cs_element_headline _id="76" ][cs_content_seo]Impact of a metabolic syndrome on the risk to develop pancreatic cancer: Recovery from metabolic syndrome was associated with a reduced risk to develop pancreatic cancer in a nationwide cohort study from Korea.\n\n[/cs_content_seo][cs_element_button _id="77" ][cs_content_seo]Link to Falk Mediacenter\n\n[/cs_content_seo][cs_element_headline _id="78" ][cs_content_seo]Event\n\n[/cs_content_seo][cs_element_text _id="79" ][cs_content_seo]No event\n\n[/cs_content_seo][/cs_element_layout_column][/cs_element_layout_row][cs_element_layout_row _id="80" ][cs_element_layout_column _id="81" ][cs_element_headline _id="82" ][cs_content_seo]Current Falk literature:\n\n[/cs_content_seo][cs_element_text _id="83" ][cs_content_seo]No literature.\n\n[/cs_content_seo][/cs_element_layout_column][/cs_element_layout_row][/cs_element_section][/cs_content]
